Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with...
NEW YORK--(BUSINESS WIRE)--May 15, 2019--
NEW YORK--(BUSINESS WIRE)--May 15, 2019--